Zhejiang Orient Gene Biotech Co Ltd (688298) - Cash Flow Conversion Efficiency

Latest as of September 2025: -0.005x

Based on the latest financial reports, Zhejiang Orient Gene Biotech Co Ltd (688298) has a cash flow conversion efficiency ratio of -0.005x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥-30.52 Million ≈ $-4.47 Million USD) by net assets (CN¥6.49 Billion ≈ $950.10 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Zhejiang Orient Gene Biotech Co Ltd - Cash Flow Conversion Efficiency Trend (2016–2024)

This chart illustrates how Zhejiang Orient Gene Biotech Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Zhejiang Orient Gene Biotech Co Ltd (688298) total liabilities for a breakdown of total debt and financial obligations.

Zhejiang Orient Gene Biotech Co Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Zhejiang Orient Gene Biotech Co Ltd ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Transcat Inc NASDAQ:TRNS	0.041x
MAS Financial Services Limited NSE:MASFIN	-0.351x
Dook Media Group Limited SHE:301025	N/A
Shenzhen Aoto Electronics Co Ltd SHE:002587	0.013x
Daily Journal Corp NASDAQ:DJCO	-0.005x
Western Copper and Gold Corp TO:WRN	0.001x
Sichuan Kexin Mechanic Electric SHE:300092	0.019x
Advanced Nano Products Co. Ltd KQ:121600	0.027x

Annual Cash Flow Conversion Efficiency for Zhejiang Orient Gene Biotech Co Ltd (2016–2024)

The table below shows the annual cash flow conversion efficiency of Zhejiang Orient Gene Biotech Co Ltd from 2016 to 2024. For the full company profile with market capitalisation and key ratios, see Zhejiang Orient Gene Biotech Co Ltd market capitalisation.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	CN¥6.79 Billion ≈ $993.80 Million	CN¥-348.33 Million ≈ $-50.97 Million	-0.051x	+75.83%
2023-12-31	CN¥7.55 Billion ≈ $1.10 Billion	CN¥-1.60 Billion ≈ $-234.43 Million	-0.212x	-158.95%
2022-12-31	CN¥8.32 Billion ≈ $1.22 Billion	CN¥3.00 Billion ≈ $438.40 Million	0.360x	-52.35%
2021-12-31	CN¥6.89 Billion ≈ $1.01 Billion	CN¥5.20 Billion ≈ $761.49 Million	0.755x	+3.44%
2020-12-31	CN¥2.45 Billion ≈ $358.72 Million	CN¥1.79 Billion ≈ $261.98 Million	0.730x	+242.35%
2019-12-31	CN¥254.13 Million ≈ $37.19 Million	CN¥54.21 Million ≈ $7.93 Million	0.213x	+0.12%
2018-12-31	CN¥208.03 Million ≈ $30.44 Million	CN¥44.33 Million ≈ $6.49 Million	0.213x	-12.27%
2017-12-31	CN¥138.12 Million ≈ $20.21 Million	CN¥33.54 Million ≈ $4.91 Million	0.243x	+103.04%
2016-12-31	CN¥98.72 Million ≈ $14.45 Million	CN¥11.81 Million ≈ $1.73 Million	0.120x	--

About Zhejiang Orient Gene Biotech Co Ltd

SHG:688298 China Medical Devices

Market Cap

$672.61 Million

CN¥4.60 Billion CNY

Market Cap Rank

#11094 Global

#3299 in China

Share Price

CN¥22.80

Change (1 day)

+2.10%

52-Week Range

CN¥21.90 - CN¥29.94

All Time High

CN¥221.47